卡介苗或阿霉素膀胱内灌注治疗浅表性膀胱癌：多中心研究中期报告

Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: multicenter study interim report.

作者信息

Khanna O P, Son D L, Mazer H, Read J, Nugent D, Cottone R, Heeg M, Rezvan M, Viek N, Friedmann M

机构信息

Department of Surgery, Hahnemann University, Philadelphia, Pennsylvania.

出版信息

Urology. 1987 Dec;30(6):520-8. doi: 10.1016/0090-4295(87)90429-8.

DOI:10.1016/0090-4295(87)90429-8

PMID:3318089

Abstract

One hundred sixteen patients with superficial bladder cancers (Stages Ta, T1, and TIS) were evaluated and treated with either intravesical bacillus Calmette-Guerin [Tice strain] (BCG) or doxorubicin hydrochloride (Adriamycin [ADR]), in a multicenter study. One hundred nine of these patients currently have follow-up. Of these, 54 were completely resected and 55 incompletely resected. For complete resections, based on recurrence rates per 100 patient months, both BCG (0.22) and ADR (0.91) worked well, although BCG had a slightly lower recurrence rate. However, for incomplete resections, BCG (0.20) had a markedly lower recurrence rate than ADR (2.52). Eighteen patients failed initial treatment, with either BCG or ADR. All have been placed on long-term therapy schedules. Of the 12 failures who currently have follow-up, 11 (92%) have either partially or completely responded with additional intravesical therapy. No patients in this study have yet required cystectomies.

摘要

在一项多中心研究中，对116例浅表性膀胱癌（Ta期、T1期和Tis期）患者进行了评估，并分别采用膀胱内灌注卡介苗[蒂氏菌株]（BCG）或盐酸多柔比星（阿霉素[ADR]）进行治疗。其中109例患者目前正在接受随访。在这些患者中，54例为完全切除，55例为不完全切除。对于完全切除的患者，以每100患者月的复发率计算，BCG（0.22）和ADR（0.91）的效果都很好，尽管BCG的复发率略低。然而，对于不完全切除的患者，BCG（0.20）的复发率明显低于ADR（2.52）。18例患者初始治疗失败，使用的是BCG或ADR。所有患者都已开始长期治疗方案。在目前接受随访的12例治疗失败患者中，11例（92%）在接受额外膀胱内治疗后有部分或完全反应。本研究中尚无患者需要进行膀胱切除术。